Mundipharma and Helsinn Group signed a licensing and distribution agreement for the anti-emetic agent Aloxi in Vietnam, extending an international collaboration. Aloxi (palonosetron hydrochloride), a 5-HT3 receptor antagonist, has been approved in Vietnam for the treatment of Chemotherapy-Induced Nausea and Vomiting (CINV), one of the most common side effects of cancer chemotherapy. “This important extension of our portfolio in Vietnam offers relief to patients suffering from the side e...